(Adnkronos) - “Conferme nei dati scientifici e nella pratica clinica per tutti i fenotipi”
Category
🗞
NewsTranscript
00:00A patient affected by atopic dermatitis that presents a location in particular such as the face, the hands and the genitals has certainly a strong impact on quality of life.
00:17So, a jack inhibitor, which are these new molecules, also called small molecules, are able to determine in a short time a clear improvement of both symptoms, such as itching and pain, as well as clinical manifestations.
00:35So, a patient affected in a week will have an important reduction of itching and in four weeks, a month, an important reduction of the clinical symptomatology, but also of the clinical expression of the disease, which are the symptoms, and therefore determines an important improvement of the patient's quality of life.
00:58I generally speak of the data that we have experienced in the daily clinical practice and of the data that are evidenced by those that are referred to in American literature.
01:13Jack inhibitors have been evidenced by the studies of phase 3, but also by our clinical practice, an effective response in short periods of time on all clinical phenotypes, in particular those that are particularly difficult, such as nodular plurigo and pulmonary eczema.
01:37A good control of the pluritus has been evidenced, already after 24 hours, so in the first days after taking the drug, and as we know, in the nodular plurigus, the pluritus is an important symptom that guides the disease.
01:53So, if I can control the pluritus, I can break that vicious circle, pluritus, scratching, and therefore it leads to a reduction of the signs and symptoms of the disease.